Loading organizations...
§ Venture Capital · 5, rue Henri-Desbrueres 91030 EVRY, France
Pre-seed fund providing capital and support for early-stage biotech startups in Île-de-France, focused on Genopole.
G1J Ile-de-France is a pre-seed venture capital fund dedicated to early-stage biotechnology startups, based in Évry, Île-de-France. The firm provides capital and strategic support to emerging life sciences companies developing innovative medicines, gene editing technologies, and oncology treatments. Operating primarily within the Genopole biopark ecosystem, the firm reported €7 million in assets under management as of 2009. Its investment portfolio features several regional biotechnology enterprises, including life sciences software developer Yubsis and oncology-focused DNA Therapeutics, which secured a €2.2 million Series A financing round with the fund's participation. The organization's investment committee has included notable industry figures such as André Choulika to help evaluate prospective life science investments. While the exact founding year and original founders remain undisclosed, the fund operates as an integral component of the broader Genopole network established in 1998.
G1J Ile-de-France has 2 tracked investments across 1 company. The latest tracked deal is $3.9M Other Equity in InnaVirVax in July 2015.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jul 17, 2015 | InnaVirVax | $3.9M Other Equity | — | FA DI E, Catherine Boule, Paris Region Venture Fund, Christian Pradeyrol |
| Feb 14, 2012 | InnaVirVax | $4.9M Series B | FA Diese, Paris Region Venture Fund, Pradeyrol Développement | CapDecisif 2 |